Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Fluidigm Europe Announces a new Technical Poster Describing its Access Array™ Chip Technology

Published: Friday, August 13, 2010
Last Updated: Friday, August 13, 2010
Bookmark and Share
New poster describes how Access Array™ chip technology has been used at NCI’s core facility to capture and sequence the entire EBV genome.

Fluidigm Europe has announced a new technical poster describing how its Access Array™ chip technology has been used by the Core Genotyping facility at the National Cancer Institute (Bethesda, MD) to capture and sequence the entire Epstein Barr Virus (EBV) genome from 4 individual patient DNA samples in a single sequence capture run.

Furthermore the authors describe how, by addition of short DNA barcodes (MIDs) to each sample during processing, they were able to pool all of their samples into a single Roche 454 sequencing run, then bioinformatically separate each sample and genomic variant during data analysis.

The ubiquitous nature of the Epstein Barr Virus (EBV) makes it a very attractive focus for genetic sequence analysis; moreover, identification of tumor-associated strains of EBV have major public impact especially in populations where EBV Malignancies are endemic. The ability to easily and cost-effectively capture and sequence the entire EBV virus from human DNA will enable researchers to vastly increase the breadth of knowledge of the virus's numerous variants.

The Fluidigm Access Array™ integrated fluidic circuit is a microfluidics chip which houses thousands of nanoscale reaction chambers. The Access Array is configured to run 48 samples and 48 primer pairs simultaneously for a total of 2304 reactions.

The authors describe how they evaluated and validated two protocols using the Access Array™ system to conduct, short and long-range capture. The short range protocol captures target lengths up to 700bp, while the long-range protocol currently captures up to 5Kb.

Overall, the NCI scientists concluded that the EBV genome sequencing project demonstrated quality sequencing results on a small scale. The implementation of a long range protocol on Fluidigm's Access Array™ system provided consistent and reliable target sequence capture as evidenced by consistent yields and high quality sequence reads on their Roche 454 sequencing platform, and can be used for other next generation sequencing platforms as well. Performing long range capture on the Access Array™ system considerably reduced the required reagents while streamlining the capture process resulting in reduced turnaround times, requiring less gDNA and reagents, and fewer manual manipulations.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Fluidigm, OpGen Collaborate
Fluidigm and OpGen have announced an agreement to collaborate on instruments and kits to test for multi-drug resistance genes in bacteria, fungi, and viruses.
Tuesday, July 14, 2015
Early Access Program for Fluidigm's New Imaging Mass Cytometry Platform
Prototypes of the product are expected to begin shipping to early access partners by the end of this year.
Sunday, August 03, 2014
Revealing the Role of “Precocious” Dendritic Cells in Inflammatory Response
Discovery makes it possible for researchers to explore how these “precocious” cells escalate the body’s immune response when the body is under attack.
Monday, July 07, 2014
Fluidigm to Acquire DVS Sciences
The acquisition consideration of approximately $207.5 million consists of a combination of Fluidigm common stock and cash.
Wednesday, January 29, 2014
Fluidigm Reports Strong Q1 2013 Results
Revenue up 33% and margins increase 300 basis points compared to Q1 2012.
Friday, May 03, 2013
Fluidigm to Develop and Supply a Custom High-throughput Prep System for HLA Typing
Custom system will ultimately enable DKMS Life Science Lab to type several thousand samples per week.
Friday, May 03, 2013
Singapore Single-Cell Research Centre Opens Door for Asian Biological Discoveries
Centre dedicated to diagnosis and treatment derived from single-cell exploration.
Monday, April 29, 2013
Fluidigm Announces $60 Million Public Offering of Common Stock
Company has closed the previously announced underwritten public offering of 4,209,000 shares of its common stock at a price to the public of $14.25 per share for gross proceeds of approximately $60 million.
Wednesday, August 22, 2012
Fluidigm Announces Unrestricted Sales into Prenatal Health
Fluidigm collaboration ends.
Tuesday, June 19, 2012
New Research Center to Focus on Mammalian Single Cell Genomics
New Center will feature a complete suite of Fluidigm single-cell tools, protocols and technologies.
Friday, June 15, 2012
Fluidigm Reports Financial Results for First Quarter 2012
Q1 total revenue up 26% compared to Q1 2011.
Monday, May 14, 2012
Fluidigm China Opens Its Doors
Company expects to rapidly build strong presence in country and improve services to Chinese customer base.
Monday, April 23, 2012
Fluidigm and AH Diagnostics Sign Distribution Deal for Scandinavia
AH diagnostics will offer Fluidigm's complete portfolio, including the complete line up of Dynamic Array(TM), Digital Array(TM) and Access Array IFCs for real-time PCR, digital PCR, single-cell gene expression, sample preparation for next-generation sequencing, and SNP genotyping.
Tuesday, January 31, 2012
Fluidigm and Life Technologies Cross-License a Broad Set of Intellectual Properties
Fluidigm Corporation announces that it has entered into a set of cross-licensing and sub-licensing agreements on a range of intellectual properties with Life Technologies.
Tuesday, July 12, 2011
Fluidigm Reports Financial Results for First Quarter 2011
Total revenue for the first quarter of 2011 was $8.7 million, an increase of 30% from $6.7 million in the first quarter of 2010.
Wednesday, May 11, 2011
Scientific News
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Cat Stem Cell Therapy Gives Humans Hope
By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Switch Lets Salmonella Fight, Evade Immune System
Researchers at the University of Illinois at Chicago have discovered a molecular regulator that allows salmonella bacteria to switch from actively causing disease to lurking in a chronic but asymptomatic state called a biofilm.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!